Inspection or harmonisation?

Baker, John; Gibson, Jane
October 2006
ICIS Chemical Business;10/9/2006, Vol. 1 Issue 38, p5
Trade Publication
The article comments on the reliance of western pharmaceutical firms on publicly funded inspections of non-U.S. and non-European Union production facilities to ensure imported quality products to use in their drugs. During the CPhl event in Paris, France, the Synthetic Organic Chemical Manufacturers Association and the European Fine Chemicals Group warned about the lack of inspections and the danger of importing pharmaceutical ingredients from plants not approved to Good Manufacturing Practice.


Related Articles

  • Guidance Sets FDA Deadlines for PMA Preapproval Factory Inspections.  // Medical Design Technology;Jul2006, Vol. 10 Issue 7, p6 

    The article reports on the draft guidance that made the Food and Drug Administration (FDA) set deadline for Produce Marketing Associations's (PMA) preapproval quality system inspection. When the draft guidance was issued on June 19, 2006, FDA gave itself 140 days to inspect the PMA manufacturing...

  • EFCG and SOCMA Urge More Inspection of Foreign API Makers. Van Arnum, Patricia // Pharmaceutical Technology;Nov2006, Vol. 30 Issue 11, p20 

    The article reports on the recommendation made by the Synthetic Organic Chemical Manufacturers Association and the European Fine Chemicals Group to increase inspections of foreign manufacturing facilities of active pharmaceutical ingredients. They urge the U.S. and European regulatory...

  • FDA Seeks Regulatory Flexibility. Wechsler, Jill // Pharmaceutical Technology;Mar2008, Vol. 32 Issue 3, p36 

    The article focuses on the regulatory flexibility sought by the Food and Drug Administration to manufacturers in the U.S. Initiatives for the regulatory flexibility include the adoption of quality-by-design approaches, acceptance of regulatory relief, and further reductions to the scope and...

  • Vials and Villains.  // Pharmaceutical Technology;Oct2007, Vol. 31 Issue 10, p20 

    The article presents a true-life cautionary story in a pharmaceutical industry where the ampul product's acidity has increased. The U.S. Department of Defense conducted an inspection to determine whether a contract could be let to the company for many products which includes injectable. However,...

  • Trends in: Foreign Inspections. Drakulich, Angie // Pharmaceutical Technology;Nov2008, Vol. 32 Issue 11, p28 

    The article discusses the result of the survey conducted by the European Federation of Pharmaceutical Industries and Associations (EFPIA) on the company spending on regulatory inspections. The survey revealed that 33% of manufacturing sites worldwide had at least three inspections in 2007, where...

  • Conference call.  // R&D Magazine;May2003, Vol. 45 Issue 5, p51 

    Presents information on the Open Conference on Analytical Methods and General United States Pharmacopeia Topics in Philadelphia, Pennsylvania in June 2003. Purpose of the meeting; Sponsors of the meeting; List of personnel who are interested in the meeting.

  • CDER Forms Up Pharmaceutical Inspectorate. Haystead, John // Pharmaceutical Technology;Apr2003, Vol. 27 Issue 4, p15 

    Reports that the U.S. Food and Drug Administration's Center for Drug Evaluation and Research has formed a uniquely-focused group of specialists to conduct inspections of pharmaceutical manufacturing facilities. Need of specialized knowledge and skills in the use of increasingly-advanced...

  • Overhauling Compliance and GMPs. Wechsler, Jill // Pharmaceutical Technology;Apr2003, Vol. 27 Issue 4, p22 

    Discusses the U.S. Food and Drug Administration's initiative to develop a risk-based approach to good manufacturing practice regulation of the pharmaceutical industry. Changes in plant inspection policies; Establishment of pharmaceutical inspectorate; Reduction in disputes involving inspection...

  • Govt. keen on having domestic regulators during US-FDA inspections.  // FRPT- Chemical Snapshot;1/25/2015, p2 

    The article reports on the move of the Indian government to request the U.S. Food and Drug Administration (FDA) to allow its domestic regulators during inspections of pharmaceutical companies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics